Gopal Anjana, Kim S Joseph
Ajmera Transplant Centre, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Can J Kidney Health Dis. 2024 May 23;11:20543581241253921. doi: 10.1177/20543581241253921. eCollection 2024.
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease characterized by excessive immune activation. It is more commonly seen in children but increasingly recognized in adults. Primary HLH relies on a genetic predisposition, whereas secondary HLH develops in the context of infections, malignancies, or autoimmune diseases. Hemophagocytic lymphohistiocytosis has been rarely described in patients on immunosuppressive therapy after kidney transplant. Here, we describe a case of HLH in a patient with a remote history of kidney transplant, triggered by a viral infection.
A 45-year-old female, with a kidney transplant in 2009 for IgA nephropathy, presented with fever, vomiting, and back pain of 1-week duration. She was on triple immunosuppression consisting of daily doses of prednisone 5 mg, azathioprine 100 mg, and tacrolimus extended release 1 mg, and a baseline creatinine of 130 µmol/L.
Initial investigations showed anemia, leukopenia, elevated serum creatinine, transaminitis, and markedly increased ferritin of 67 600 µg/L which prompted a bone marrow biopsy to rule out HLH. The bone marrow showed an increased proportion of CD68+ cells (macrophages) with more than 5 in 1000 hemophagocytic macrophages. Her soluble IL-2 receptor (CD25) level was 3406 pg/mL (606-2299 pg/mL) which was mildly elevated. She fulfilled 4 of the 8 criteria for HLH and with an H score was 223 which suggested a diagnosis of HLH with 96.9% probability. An extensive secondary workup for possible triggers for HLH led to a swab from genital ulcers that was positive for herpes simplex virus (HSV) type 2. The polymerase chain reaction (PCR) in the blood for HSV type 2 was also positive.
Given the diagnosis of HSV type 2 as the putative trigger for HLH, she was started on parenteral acyclovir for 2 weeks followed by oral valacyclovir for 2 more weeks. In the context of infection, the azathioprine was stopped while low-dose steroid and tacrolimus were continued.
With the initiation of treatment for HSV infection, leukopenia, creatinine, and transaminases improved along with ferritin levels. At her 6-month follow-up, her blood counts and liver enzymes had normalized, and ferritin was 566 µg/L.
Hemophagocytic lymphohistiocytosis is a rare disease in kidney transplant recipients with a high mortality rate. It can occur even in remote kidney transplant recipients so a high degree of suspicion is necessary to lead to a prompt diagnosis. Infections are common triggers for secondary HLH. Early identification and treatment of the triggering infection may improve outcomes.
噬血细胞性淋巴组织细胞增生症(HLH)是一种以过度免疫激活为特征的危及生命的疾病。它在儿童中更常见,但在成人中也越来越受到关注。原发性HLH依赖于遗传易感性,而继发性HLH则在感染、恶性肿瘤或自身免疫性疾病的背景下发生。噬血细胞性淋巴组织细胞增生症在肾移植后接受免疫抑制治疗的患者中很少被描述。在此,我们描述一例有肾移植病史的患者发生的HLH,由病毒感染引发。
一名45岁女性,2009年因IgA肾病接受肾移植,出现发热、呕吐和持续1周的背痛。她接受三联免疫抑制治疗,每日剂量为泼尼松5毫克、硫唑嘌呤100毫克和缓释他克莫司1毫克,基线肌酐为130微摩尔/升。
初步检查显示贫血、白细胞减少、血清肌酐升高、转氨酶升高以及铁蛋白显著升高至67600微克/升,这促使进行骨髓活检以排除HLH。骨髓显示CD68 +细胞(巨噬细胞)比例增加,每1000个噬血细胞性巨噬细胞中超过5个。她的可溶性白细胞介素 - 2受体(CD25)水平为3406皮克/毫升(606 - 2299皮克/毫升),轻度升高。她符合HLH 8项标准中的4项,H评分为223,提示HLH诊断概率为96.9%。对HLH可能的触发因素进行广泛的二次检查发现,生殖器溃疡拭子检测单纯疱疹病毒2型(HSV)呈阳性。血液中HSV 型2的聚合酶链反应(PCR)也呈阳性。
鉴于诊断为HSV 2型是HLH的假定触发因素,她开始接受静脉注射阿昔洛韦治疗2周,随后口服伐昔洛韦再治疗2周。在感染的情况下,停用硫唑嘌呤,继续使用低剂量类固醇和他克莫司。
随着HSV感染治疗的开始,白细胞减少、肌酐和转氨酶以及铁蛋白水平均有所改善。在6个月的随访中,她的血细胞计数和肝酶恢复正常,铁蛋白为566微克/升。
噬血细胞性淋巴组织细胞增生症在肾移植受者中是一种罕见疾病,死亡率高。即使在远期肾移植受者中也可能发生,因此需要高度怀疑以实现及时诊断。感染是继发性HLH的常见触发因素。早期识别和治疗触发感染可能改善预后。